

-156-

CLAIMS

What is claimed is:

1. A method for treating a neurodegenerative disease in a human, comprising administering to said human at least one anti-TNF monoclonal antibody, or a
5 TNF binding fragment thereof.
2. A method of Claim 1, wherein the TNF-mediated neurodegenerative disease is multiple sclerosis.
3. A method of Claim 1, wherein the TNF-mediated disease is selected from AIDS
10 deméntia complex, a demyelinating disease, multiple sclerosis, acute transverse myelitis, an extrapyramidal disorder, a cerebellar disorder, a lesion of the corticospinal system, a disorder of the basal ganglia, a cerebellar disorder, a hyperkinetic movement disorder, Huntington's Chorea, senile chorea, a drug-induced movement disorder, a hypokinetic movement disorder, Parkinson's disease, progressive supranucleo palsy, a structural lesion of the cerebellum, a
15 spinocerebellar degeneration, spinal ataxia, Friedreich's ataxia, a cerebellar cortical degeneration, a multiple systems degeneration, a systemic disorder, Refsum's disease, abetalipoproteinemia, ataxia telangiectasia, a mitochondrial multi-system disorder, a demyelinating core disorder, acute transverse myelitis, a disorder of the motor unit, a neurogenic muscular atrophy, anterior horn cell degeneration, amyotrophic lateral sclerosis, infantile spinal muscular atrophy,
20 juvenile spinal muscular atrophy, Alzheimer's disease, Down's Syndrome, a diffuse Lewy body disease, senile dementia of Lewy body type, Wernicke-Korsakoff syndrome, chronic alcoholism, Creutzfeldt-Jakob disease, subacute sclerosing panencephalitis, Hallerrorden-Spatz disease or dementia pugilistica.

0975.1005-010

Sub

A2